Kardigan, Inc. is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. The company operates a discovery and translational research platform and maintains a pipeline of late-stage clinical candidates designed to modify the underlying drivers of disease rather than merely managing symptoms. Kardigan integrates the AI and real-world data platform of Prolaio to inform clinical trial design and enhance its drug development capabilities. Its therapeutic focus is on creating novel medicines for underserved cardiovascular conditions, aiming to advance beyond current standard-of-care approaches.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Biotechnology Homepage ir.kardigan.bio
Sector Healthcare IR page ir.kardigan.bio
Tags
cardiovascular disease, precision therapeutics, clinical-stage, drug discovery, ai drug development, real-world data, Prolaio
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable —
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 19
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure Q3 2026 Q2 2026
Assets 649.251M 721.786M
Net profit -58.568M -116.236M
Free cash flow -60.369M —

Figure Q3 2026 Q2 2026
Share price 14.75 23.85
P/FCF -5.71 —

Filed figures

Figure Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 13.8M
Cash and deposits (USD) 49.8M 109M
Intangible assets (USD) — 23.2M
Right-of-use assets (USD) — 11.7M
Reported Aug 11, 2026 Aug 11, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Completed enrollment in Cohort 2 of Phase 2b danicamtiv KINSHIP-DCM trial, topline data expected in 2Q 2027; Phase 3 enrollment underway in both cohorts

Completed enrollment in Phase 2b ataciguat KATALYST-AV trial; Week 48

topline data expected in 2H 2027

Cash position of $591.4 million supports multiple data readouts across all programs through 2027 and initiation of Phase 3 clinical trials

SOUTH SAN FRANCISCO, Calif., and PRINCETON, N.J., Nov 12, 2026 — Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan” or “the Company”), a precision cardiovascular company, today reported financial results for the third quarter ended September 30, 2026, and provided recent business updates.

“We made meaningful progress this quarter in advancing our portfolio of late-stage cardiovascular programs for people who urgently need better treatment options,” said Tassos Gianakakos, co-founder, chief executive officer and board chair of Kardigan. “Completing enrollment in the Phase 2b portion of our Phase 2b/3 adaptive KINSHIP-DCM trial is a significant milestone for danicamtiv and for people with genetic dilated cardiomyopathy.

Primary endpoint of aortic valve calcium in KATALYST-AV to be

assessed at Week 48 alongside aortic valve area and measures of cardiac structure and function; topline data expected 2H 2027

Novel real-world data help identify key markers of risk, rate of progression of disease and worsening outcomes in aortic stenosis, informing patient selection criteria and potential endpoints for Phase 3 registrational trial

Company to host an investor webcast while at the American Heart Association Scientific Sessions on Saturday, November 7, 2026, at 8:00 AM ET

SOUTH SAN FRANCISCO, Calif., and PRINCETON, N.J., Nov. 6, 2026 — Kardigan®, Inc. (Nasdaq: KARD), a precision cardiovascular company, today announced enrollment completion in the Phase 2b KATALYST-AV trial of ataciguat in people with aortic stenosis (AS). The Company also shared insights from a pre-planned analysis of the trial’s baseline data, as well as new evidence on disease progression from one of the largest real-world analyses conducted in approximately 45,000 people with AS.

September 30, 2026

PDF Version

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Sep. 30, 2026-- Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a precision cardiovascular company, announced today the appointment of Kristin Reinke to its Board of Directors, where she will serve as chair of the Audit Committee. As part of the Board’s public company evolution, Doug Giordano will be stepping down from the Board. Both Ms. Reinke’s appointment and Mr. Giordano’s departure are effective as of September 29, 2026.

“Kristin's proven track record leading AI-driven transformation at global scale will be a great asset to help us achieve our mission of changing the future of cardiovascular care. Her experience turning technology into an operational advantage will be invaluable as we integrate Prolaio's data and analytics platform into our product development, and her financial governance expertise will help guide our late-stage pipeline toward potential commercialization. We're thrilled to welcome Kristin to the Kardigan Board and are fortunate to have her chair our Audit Committee,” said Tassos Gianakakos, co-founder, chief executive officer, and chair of the board of Kardigan. “We also would like to thank Doug, a founding member of our Board, for his profound impact over the last few years."

Ms. Reinke is currently vice president of finance at Google, where she leads the application of AI to modernize and scale the company's finance organization. A member of Google's finance leadership team since 2005, she has held roles spanning global FP&A, capital allocation, and controllership, helping the company grow from a startup into a multibillion-dollar global enterprise. She previously held leadership roles at Oracle and began her career at Arthur Andersen. Ms. Reinke serves on the board of Everly Health as an independent director and the audit committee chair. She is a CPA and holds a bachelor's degree in accounting from Michigan State University.

About Kardigan

Kardigan is a clinical-stage precision cardiovascular company developing medicines that target the root cause of diseases where no approved treatments exist. Led by a proven and experienced management team, Kardigan is reimagining cardiovascular drug discovery and development through an integrated approach that unites deep cardiovascular biology, real-world patient data, and advanced analytics to enable more precise, efficient, and informed development of novel therapies. Learn more about Kardigan and its mission at Kardigan.bio.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260930134179/en/

Media: Michael Bachner Executive Director, Corporate Communications +1 (609) 664-7308 [email protected]

Investors: Clayton Robertson Vice President, Investor Relations [email protected]

Source: Kardigan, Inc.

Search Investors

Prompts

Kardigan, Inc. (ticker KARD), listed in United States.

ETFs Holding Kardigan, Inc.

ETF Weight in ETF Shares Market value As of
GDOC 0.49% 4,775 $ 96.264K Aug 31, 2026
TMED 0.28% 2,695 $ 64.276K Jun 30, 2026
GSC 0.26% 35,720 $ 720.115K Aug 31, 2026